A phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral MDM2 Inhibitor, in Japanese Subjects with Advanced Solid Tumors or Lymphomas
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 29 Mar 2018
At a glance
- Drugs DS 3032b (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 27 Mar 2018 Planned End Date changed from 31 Mar 2017 to 31 Mar 2019.
- 13 Feb 2017 Planned End Date changed from 30 Sep 2016 to 31 Mar 2017.
- 13 Feb 2017 Status changed from recruiting to active, no longer recruiting.